Menquadfi (Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi)

Menquadfi is used to prevent meningococcal disease caused by serogroup C, a bacterial infection that can lead to severe invasive illness.

• Invasive meningococcal disease (serogroup C): provides active immunity to prevent infection.
• Outbreak control in communities: reduces transmission during serogroup C outbreaks.
• Travelers to endemic regions: protects individuals traveling to areas with high serogroup C prevalence.
• Adolescents and young adults: offers long‑lasting protection in age groups at increased risk.

• Menquadfi contains the capsular polysaccharide of Neisseria meningitidis serogroup C covalently linked to tetanus toxoid, creating a conjugate that is recognized by the immune system as a protein antigen. This conjugation enables T‑cell dependent activation of B cells, leading to robust production of serogroup‑specific IgG antibodies and immunological memory that neutralize the bacteria upon exposure.

Menquadfi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness and swelling: localized erythema and edema.
• Fever: low‑grade temperature rise within 24‑48 hours.
• Headache: transient mild headache.
• Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurological disorder with muscle weakness.
• Seizures: infrequent occurrence of convulsive episodes.
• Hypotension: sudden drop in blood pressure post‑vaccination.

Before administering Menquadfi, healthcare providers should observe several precautionary measures to ensure safety.

• Allergy assessment: avoid use in individuals with severe hypersensitivity to any vaccine component.
• Pregnancy considerations: safety not established; weigh benefits against potential risks.
• Immunocompromised patients: vaccine may elicit a reduced immune response.
• Concomitant vaccines: separate administration from live vaccines by at least 4 weeks.
• Blood product interaction: postpone immunoglobulin therapy for 4 weeks after vaccination.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menquadfi can interact with certain medicines and vaccines, requiring attention to timing and monitoring.

Major Interactions (Avoid)

• Live bacterial vaccines: should not be given concurrently; separate by at least 4 weeks.
• Immunoglobulin products: avoid administration within 4 weeks before or after vaccination.

Moderate Interactions (Monitor Closely)

• Other inactivated vaccines: may be co‑administered but monitor for increased reactogenicity.
• Immunosuppressive therapy: may diminish vaccine‑induced immunity; assess antibody response.
• Antipyretic agents: can mask fever, a common post‑vaccination sign; use judiciously.